Final analysis of the Phase III GHSG HD21 trial: PET-guided
brecadd vs. ebeacopp in advanced-stage classical Hodgkin
lymphom
152
primary Phase 3 results from the epcore FL-1 trial of
epcoritamab with rituximab and lenalidomide (R2) versus
R2 for relapsed or refractory follicular lymphom
466
3-year follow-up of the S1826 study confirms improved
progression-free survival with nivolumab-AVD compared to
brentuximab vedotin-AVD in advanced stage classic Hodgkin
lymphoma
151
ASH 2025
LINFOMA
ASH 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Final analysis of the randomized phase 2 ROSEWOOD study
of zanubrutinib + obinutuzumab vs obinutuzumab
monotherapy in patients with relapsed/refractory follicular
lymphoma
227